Oncoinvent ASA: Grant of share options - mandatory notification of trade

Oncoinvent ASA ("Oncoinvent" or the "Company") has today granted 3,560,000 share options under its long term share incentive scheme for employees (the "Option Program"), each with a strike price of NOK 2.4991 of these 2,210,000 share options were granted to primary insiders of the Company. For more information about the grant of share options to primary insiders, see the attached forms. Following today's grant, a total of 4,789,808 share options have been granted under the Option Program. This information is subject to the disclosure requirements pursuant to article 19 of the regulation EU 596/2014 (the EU Market Abise Regulation) and section 5-12 of the Norwegian Securities Trading Act. About Oncoinvent Oncoinvent ASA is a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver powerful radiation directly to cancer cells. The Company’s lead product candidate, Radspherin®, is being advanced through clinical development by a team with experience from all stages of radiopharmaceutical development. Internal manufacturing and supply chain capabilities have been established, which now have the capacity to supply Radspherin® for multi-center phase 2 clinical studies. For further information, please contact: Øystein Soug, Chief Executive Officer Email: soug@oncoinvent.com Tore Kvam, Chief Financial Officer Email: kvam@oncoinvent.com